| __timestamp | Blueprint Medicines Corporation | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 6620800000 |
| Thursday, January 1, 2015 | 14456000 | 6533000000 |
| Friday, January 1, 2016 | 19218000 | 6452000000 |
| Sunday, January 1, 2017 | 27986000 | 6588100000 |
| Monday, January 1, 2018 | 47928000 | 5975100000 |
| Tuesday, January 1, 2019 | 96388000 | 6213800000 |
| Wednesday, January 1, 2020 | 157743000 | 6121200000 |
| Friday, January 1, 2021 | 195293000 | 6431600000 |
| Saturday, January 1, 2022 | 237374000 | 6440400000 |
| Sunday, January 1, 2023 | 295141000 | 6941200000 |
| Monday, January 1, 2024 | 359272000 | 8593800000 |
Unleashing insights
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Eli Lilly and Company, a stalwart in the industry, and Blueprint Medicines Corporation, a rising star, offer a fascinating study in contrasts. Over the past decade, Eli Lilly has consistently managed its SG&A costs, maintaining an average of approximately $6.4 billion annually. In contrast, Blueprint Medicines, with its rapid growth trajectory, has seen its SG&A expenses increase from a modest $7.9 million in 2014 to nearly $295 million in 2023, reflecting a staggering growth of over 3,600%. This comparison highlights the different challenges faced by established giants and emerging innovators in balancing growth with cost management. As Blueprint Medicines scales, its ability to control SG&A expenses will be pivotal in its quest to compete with industry leaders like Eli Lilly.
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Insmed Incorporated and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.